Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
August 4th, 2022
3.2K views
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as a promising in vitro model for drug-induced cardiotoxicity screening and disease modeling. Here, we detail a protocol for measuring the contractility and electrophysiology of hiPSC-CMs.
Overview
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are a reliable model for assessing cardiac safety during drug development. This article details methodologies for evaluating the contractility and electrophysiology of hiPSC-CMs.
Key Study Components
Area of Science
- Cardiac safety assessment
- Drug-induced cardiotoxicity screening
- Disease modeling
Background
- hiPSC-CMs provide a human-based model for pre-clinical assessments.
- They enhance the accuracy of toxicity predictions for drug candidates.
- Established methodologies allow for comprehensive functional investigations.
- These cells are crucial for precision medicine applications.
Purpose of Study
- To improve cardiac safety evaluations in drug development.
- To provide a detailed protocol for measuring hiPSC-CM contractility.
- To assess the electrophysiological properties of hiPSC-CMs.
Methods Used
- Culturing hiPSC-CMs for at least 10 days prior to measurements.
- Utilizing a temperature controller set at 37 degrees Celsius.
- Measuring contractility and electrophysiological responses.
- Implementing methodologies for comprehensive functional analysis.
Main Results
- hiPSC-CMs demonstrated reliable contractility measurements.
- Electrophysiological characteristics were successfully assessed.
- Findings support the use of hiPSC-CMs in toxicity screening.
- Results indicate potential for improved pre-clinical safety evaluations.
Conclusions
- hiPSC-CMs are effective for cardiac safety assessments.
- The methodologies established can enhance drug development processes.
- Future studies may further validate these findings in clinical settings.
Frequently Asked Questions
What are hiPSC-CMs?
Human-induced pluripotent stem cell-derived cardiomyocytes are heart cells derived from stem cells that can be used for research and drug testing.
Why are hiPSC-CMs important for drug development?
They provide a human-based model that improves the accuracy of cardiac safety assessments during drug development.
How long should hiPSC-CMs be cultured before measurements?
They should be cultured for at least 10 days prior to taking measurements.
What temperature is recommended for measuring hiPSC-CMs?
The temperature controller should be set at 37 degrees Celsius.
What methodologies are used to assess hiPSC-CMs?
Methods include measuring contractility and electrophysiological properties to evaluate their functionality.
Can hiPSC-CMs be used for precision medicine?
Yes, they are crucial for precision medicine applications due to their human-based nature.
Executive Industry Relevance
Human iPSC-derived cardiomyocytes (hiPSC-CMs) enable predictive, human-relevant cardiac safety assessment early in drug discovery, addressing the translational gap left by animal models. Integrating microelectrode array and patch clamp recordings with hiPSC-CMs provides quantitative, mechanistic insights into drug-induced cardiotoxicity. This approach supports risk-adjusted portfolio decisions and enhances confidence in preclinical cardiac liability screening.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of cardiac electrophysiological pathways in a human cellular context.
- Supports mechanistic de-risking by quantifying drug effects on action potentials and field potentials.
- Facilitates functional target validation for cardiac safety liabilities.
- Improves predictive confidence for candidate triage based on human-specific data.
Screening & Assay Development
- Establishes validated, reproducible hiPSC-CM assays for compound screening.
- Delivers quantitative outputs such as beat period, field potential duration, and spike amplitude.
- Enables scalable, high-content screening using microelectrode arrays.
- Supports standardization of cardiac safety assays across discovery teams.
Translational & Preclinical Research
- Aligns preclinical cardiac safety models with human disease relevance.
- Provides continuity from early discovery through preclinical validation using the same cell platform.
- Reduces translational risk by leveraging patient- or disease-specific hiPSC-CMs.
- Enables assessment of drug-induced cardiotoxicity in genetically diverse backgrounds.
Pipeline & Workflow Integration
Microelectrode array and patch clamp recordings on hiPSC-CMs integrate into the discovery-to-preclinical continuum, bridging early safety assessment and translational research.
- Discovery Biology: Supports hypothesis testing and mechanistic clarification of cardiac drug effects.
- Screening: Provides reproducible, quantitative readouts for compound prioritization.
- Analytics: Generates actionable metrics such as action potential duration and calcium transient parameters.
- Translational Research: Maintains model continuity for biomarker alignment and disease modeling.
- Enterprise Reuse: Establishes a reusable, standardized platform for cardiac safety evaluation across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac safety assessment.
- Operational Value: Delivers standardized, scalable, and reproducible functional assays.
- Strategic Value: Enables earlier go/no-go decisions and reduces late-stage attrition due to cardiac liabilities.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of drug candidates.
Implementation Considerations
- Requires expertise in hiPSC-CM culture and electrophysiological recording techniques.
- Needs access to microelectrode array and patch clamp instrumentation with analytical software.
- Demands cross-team standardization of assay protocols and data analysis.
- Adaptation may be needed for different hiPSC-CM lines or disease models.
- Dependent on high-purity, well-beating hiPSC-CM preparations for reliable outputs.
Biopharma FAQs
Why does null hypothesis testing matter for field potential analysis?
Null hypothesis testing in field potential analysis enables objective evaluation of drug-induced changes in cardiac electrophysiology, supporting robust target validation and minimizing false positives in safety assessment.
How does independent variable isolation fit microelectrode array workflows?
Isolating variables such as compound concentration or stimulation parameters in microelectrode array assays ensures that observed effects on beat period or field potential duration are attributable to the test article, strengthening discovery-stage decision making.
What do quantitative action potential measurements enable in preclinical R&D?
Quantitative action potential metrics, including amplitude and duration, provide mechanistic insight into drug effects on cardiac cells, enabling comparative analysis and predictive safety profiling across candidate compounds.
Why are replication requirements critical for cross-team cardiac safety studies?
Replication of hiPSC-CM functional assays ensures reproducibility and reliability of cardiac safety data, facilitating cross-functional collaboration and consistent portfolio advancement decisions.
Which statistical analysis capabilities are required before implementing calcium transient assays?
Robust statistical analysis of calcium transient parameters, such as amplitude and decay tau, is essential to distinguish true drug effects from baseline variability, supporting confident implementation in safety screening workflows.
Chapters in this video
0:04
Introduction
0:56
Measurement of hiPSC‐CM Contraction Motion
1:59
Measurement of hiPSC‐CM Field Potential
4:16
Measurement of hiPSC‐CM Action Potential
6:22
Measurement of hiPSC‐CM Ca2+ Transient
8:09
Results: Contraction Motion, Microelectrode Array, Patch Clamp Recordings and Ca2+ Imaging on hiPSC‐CMs
9:47
Conclusion
